Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al
Int J Infect Dis. 2021 Apr:105:686-687.
doi: 10.1016/j.ijid.2021.02.028.
Epub 2021 Feb 15.